4-Methylpiperidine → 4-(2,6-Diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-2-(4-methyl-piperidin-1-yl)-phenylamine

HRID 340583Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 340583
C(OC(=O)[NH:7][C:8]1[CH:13]=[CH:12][C:11]([CH:14]2[CH2:19][N:18]([CH2:20][CH3:21])[S:17](=[O:23])(=[O:22])[N:16]([CH2:24][CH3:25])[CH2:15]2)=[CH:10][C:9]=1Br)(C)(C)C.[CH3:28][CH:29]1[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]1>>[CH2:24]([N:16]1[CH2:15][CH:14]([C:11]2[CH:12]=[CH:13][C:8]([NH2:7])=[C:9]([N:32]3[CH2:33][CH2:34][CH:29]([CH3:28])[CH2:30][CH2:31]3)[CH:10]=2)[CH2:19][N:18]([CH2:20][CH3:21])[S:17]1(=[O:23])=[O:22])[CH3:25]

Komponenten

3

Versuchsvorschrift

The title compound is prepared from [2-bromo-4-(2,6-diethyl-1,1-dioxo-1λ6-[1,2,6]thiadiazinan-4-yl)-phenyl]-carbamic acid tert-butyl ester (as prepared in the previous step) and 4-methylpiperidine following the literature procedure of Buchwald (Org. Lett., 4, 2885-8 (2002)). The residue obtained is purified by silica gel chromatography with an appropriate solvent mixture. After isolation, removal of the BOC protecting group from the resulting intermediate is carried out by stirring at RT in TFA-DCM (1:2), monitoring by TLC for completion, and then concentration in vacuo.

Aufarbeitung

  1. customThe residue obtained
  2. customis purified by silica gel chromatography with an appropriate solvent mixture
  3. customAfter isolation, removal of the BOC protecting group from the resulting intermediate
  4. concentrationconcentration in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-ae98f35c59924855b8375f825baea0ec
Quelldatensatz
uspto-grants-2014_11
Patentnummer
US08895584B2

Notizen zur Reaktion

Wird geladen…